Detalhe da pesquisa
1.
Moving toward disease modification in polycythemia vera.
Blood
; 142(22): 1859-1870, 2023 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729609
2.
MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.
Blood
; 139(2): 205-216, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34359073
3.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
4.
Risk factors for disease progression and treatment goals in polycythemia vera.
Clin Adv Hematol Oncol
; 22(1): 31-42, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38294739
5.
Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression.
Int J Mol Sci
; 25(7)2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38612873
6.
Acute myeloid leukemia: Current understanding and management.
JAAPA
; 37(1): 34-39, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38128137
7.
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
Haematologica
; 108(10): 2730-2742, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37165840
8.
Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012-2022.
Acta Haematol
; : 1, 2023 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37751713
9.
Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study.
Future Oncol
; 19(11): 763-773, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37161798
10.
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
Cancer
; 128(14): 2717-2727, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385124
11.
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
Blood
; 135(19): 1696-1703, 2020 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107559
12.
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica
; 107(7): 1599-1607, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551507
13.
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Ann Hematol
; 101(5): 935-951, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35344066
14.
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Ann Hematol
; 101(1): 139-146, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34622316
15.
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Future Oncol
; 18(22): 2393-2402, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510486
16.
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Future Oncol
; 2022 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36416118
17.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Future Oncol
; 18(27): 2987-2997, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950489
18.
The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands.
Int J Mol Sci
; 23(24)2022 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36555547
19.
Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Oncologist
; 26(5): 406-421, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792103
20.
Oral idasanutlin in patients with polycythemia vera.
Blood
; 134(6): 525-533, 2019 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31167802